Verastem, Inc.

Home » Verastem, Inc.

Secondary

Verastem, Inc.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways.

Symbol

VSTM

Last Closing Price
$3.65

Shares
8,400,000

Effective Date
December 15, 2017

Underwriters
BTIG

To view the prospectus for Verastem, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253